Allurion Technologies (ALUR) AI Stock Analysis

• Market Cap: $8.61M
• Dividend Yield: N/A
• Average Volume (3M): 88.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.71
• Revenue Growth: -50.49%
• EPS Growth: 39.93%
• Country: US
• Employees: 134
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -1.53
• Shares Outstanding: 12,279,181
• 10 Day Avg. Volume: 45,410
• 30 Day Avg. Volume: 88,723
• PEG Ratio: 0.01
• Price to Book (P/B): -0.31
• Price to Sales (P/S): 0.75
• P/FCF Ratio: -0.56
• Enterprise Value/Market Cap: 3.78
• Enterprise Value/Revenue: 1.89
• Enterprise Value/Gross Profit: 3.10
• Enterprise Value/Ebitda: -0.97
• 1Y Price Target: $5.50
• Price Target Upside: 685.71% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -1.32
• Revenue Forecast (FY): $16.81M

• Rating: 49 Neutral
• Price Target: $1.50 ▲(114.29% Upside)
• Action: Reiterated Date: 01/13/26
• Date: Action: Reiterated 01/13/26

Overall score is held back primarily by weak financial performance: contracting revenue, large ongoing losses, heavy cash burn, and negative equity. Offsetting factors include improving cost control and constructive FDA/regulatory and balance-sheet restructuring progress discussed on the earnings call, plus moderately positive technical momentum. Valuation remains difficult to support due to negative earnings and no dividend yield provided.

Positive Factors

Non‑surgical, provider‑delivered product + digital program

Allurion’s core offering is a non‑endoscopic, swallowable balloon paired with remote monitoring and coaching delivered through providers. This business model creates a differentiated, recurring service bundle and lowers procedural complexity, aiding adoption and scaling across clinics over months to years.

Strong product‑level gross margins

Sustained gross margins above 60% indicate attractive product economics at the unit level. If revenue stabilizes, these margins support operating leverage, fund R&D and commercialization, and make break‑even achievable without relying solely on price appreciation.

Regulatory progress and strategic combo therapy partnerships

Clear FDA milestones reduce a major commercialization barrier for the Allurion Smart Capsule. Concurrent partnerships to facilitate GLP‑1 access and development of a drug‑eluting balloon position the company to offer clinically superior combination therapies, strengthening long‑term market potential.

Negative Factors

Multi‑year declining revenue

A sharp multi‑year revenue decline erodes scale, reduces per‑unit absorption of fixed costs, and weakens clinic penetration. Sustained top‑line contraction materially raises the time and capital required to restore growth and threatens long‑term viability absent successful commercial re‑acceleration.

Large, persistent cash burn

Material negative operating and free cash flow indicate the business consumes substantial liquidity to operate. Even with improvement from prior years, ongoing cash burn increases dependency on external financing and constrains investment in sales, marketing, and product development over the next several quarters.

Highly stressed balance sheet and leverage risk

Negative equity and meaningful debt relative to assets limit financial flexibility and elevate refinancing and dilution risk. Even planned debt‑for‑preferred exchanges reduce near‑term cash interest but may leave governance and capital structure constraints that hinder long‑term strategic options.

Allurion Technologies Business Overview & Revenue Model

Company Description

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.

How the Company Makes Money

Allurion Technologies generates revenue through the sale of its medical devices, particularly the Allurion Balloon and associated services. The company typically sells its products directly to healthcare providers, hospitals, and clinics, which then offer these solutions to patients seeking weight loss options. Additionally, Allurion has developed partnerships with healthcare institutions and professionals to enhance the distribution of its products and services, creating a network that expands its market reach. The company may also generate income through subscription services for ongoing support and coaching, contributing to a recurring revenue model. Furthermore, Allurion's collaborations with insurance companies can facilitate reimbursement for its products, enhancing access to patients and driving sales.

Allurion Technologies Financial Statement Overview

Summary

Financials are highly stressed: TTM revenue declined to ~$17.2M (down ~13.6% vs. prior period) and remains in a multi-year downtrend, while losses are large (TTM EBIT about -$41.0M; net loss about -$43.3M) and cash burn is substantial (TTM operating/free cash flow about -$36.9M). The balance sheet shows negative equity (about -$82.9M TTM) and sizable debt versus a small asset base, elevating refinancing/dilution risk despite relatively strong gross margins (~61% TTM).

Income Statement

TTM (Trailing-Twelve-Months) revenue fell to ~$17.2M (down ~13.6% vs. prior period), continuing a multi-year downtrend from ~$64.2M in 2022 and ~$53.5M in 2023 to ~$32.1M in 2024. While gross margin remains relatively strong (~61% TTM; ~67% in 2024), operating losses are very large (TTM EBIT of about -$41.0M and net loss of about -$43.3M), implying costs are far out of scale versus the current revenue base. Overall profitability and trajectory remain weak despite decent product-level margin.

Balance Sheet

The balance sheet is highly stressed with negative stockholders’ equity in every recent period (about -$82.9M TTM and -$78.0M in 2024), which is a major solvency red flag. Total debt remains sizable (about $33.4M TTM; $37.9M in 2024) relative to a small asset base (about $18.1M TTM). Negative equity makes leverage metrics difficult to interpret in a conventional way, but the headline takeaway is limited balance-sheet flexibility and elevated financing risk.

Cash Flow

Cash generation is weak with materially negative operating cash flow and free cash flow (TTM operating cash flow and free cash flow both about -$36.9M; 2024 operating cash flow about -$42.3M and free cash flow about -$42.9M). Cash burn has improved versus 2023 (free cash flow about -$65.6M), but the business is still consuming significant cash to operate. With losses and negative free cash flow persisting, ongoing funding needs appear likely unless the cost structure or revenue trajectory improves meaningfully.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	17.21M	32.11M	53.47M	64.21M	38.24M	0.00
Gross Profit	10.49M	21.50M	41.50M	50.73M	29.19M	0.00
EBITDA	-33.37M	-22.17M	-69.03M	-32.28M	-8.01M	201.13K
Net Income	-43.29M	-26.15M	-80.61M	-37.74M	-12.39M	-5.17K
Balance Sheet
Total Assets	18.14M	32.81M	71.71M	51.37M	39.35M	329.96K
Cash, Cash Equivalents and Short-Term Investments	6.14M	15.38M	38.04M	7.68M	25.84M	47.09K
Total Debt	33.39M	37.92M	41.86M	59.53M	26.14M	170.00K
Total Liabilities	101.07M	110.79M	142.20M	83.68M	73.64M	310.13K
Stockholders Equity	-82.93M	-77.98M	-70.49M	-32.31M	-34.28M	19.83K
Cash Flow
Free Cash Flow	-36.90M	-42.91M	-65.59M	-48.53M	-15.24M	-40.00
Operating Cash Flow	-36.90M	-42.30M	-63.98M	-46.98M	-14.33M	-35.00
Investing Cash Flow	0.00	-611.00K	-1.61M	-1.55M	-912.00K	0.00
Financing Cash Flow	14.32M	20.21M	95.99M	30.54M	28.95M	47.13K

Allurion Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALUR, the sentiment is Negative. The current price of 0.7 is below the 20-day moving average (MA) of 1.17, below the 50-day MA of 1.39, and below the 200-day MA of 2.04, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 35.23 is Neutral, neither overbought nor oversold. The STOCH value of 12.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALUR.

Allurion Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALUR	49 Neutral	$8.61M	-0.10	―	―	-50.49%	39.93%
IRIX	46 Neutral	$24.24M	-4.66	-139.29%	―	4.58%	55.26%
XAIR	45 Neutral	$9.38M	-0.16	-240.75%	―	147.74%	73.23%
CODX	44 Neutral	$4.82M	-0.08	-62.12%	―	-87.84%	29.16%
NVNO	42 Neutral	$6.68M	-0.26	-57.19%	―	―	18.94%
SINT	40 Underperform	$10.86M	-0.41	-204.04%	―	-60.89%	94.49%

Allurion Technologies Corporate Events

Allurion Shareholders Approve Governance Changes and Capital Actions

At its annual meeting on December 18, 2025, Allurion Technologies, Inc. re-elected directors Omar Ishrak, Douglas Hudson and R. Jason Richey to serve until the 2028 annual meeting and ratified Deloitte & Touche LLP as its independent auditor for the 2025 fiscal year. Shareholders also approved an amended and restated 2023 Stock Option and Incentive Plan that increases the share pool, extends the plan term, revises the fully diluted share definition and lowers non-employee director compensation limits, as well as the repricing of certain existing stock options. In addition, investors authorized the issuance of common shares upon conversion of Series B preferred stock and the exercise of private placement warrants to ensure compliance with New York Stock Exchange listing rules, and backed a share consolidation authorization allowing the board to implement a reverse stock split in a range of 1-for-1.5 to 1-for-20, steps that collectively enhance the company’s capital structure flexibility and support its continued listing and governance framework.

The most recent analyst rating on (ALUR) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Allurion Technologies stock, see the ALUR Stock Forecast page.

Allurion Technologies Secures $5M in New Funding

On November 11, 2025, Allurion Technologies entered into a securities purchase agreement to sell shares and warrants for approximately $5 million, aiming to strengthen its balance sheet. Concurrently, the company agreed to exchange outstanding debt for convertible preferred equity with RTW Investments, which will allow RTW to convert debt into Series B Preferred Stock, enhancing Allurion’s financial position. These strategic financial maneuvers are part of Allurion’s broader efforts to secure FDA approval for its products and position itself for long-term success in the weight-loss industry.

The most recent analyst rating on (ALUR) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Allurion Technologies stock, see the ALUR Stock Forecast page.